Clinical Trial Update: BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of Onivyde with metronomic temozolomide in recurrent glioblastoma has been terminated; results posted prior to termination.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioblastoma Multiforme

Drugs mentioned

• Onivyde (irinotecan hydrochloride liposome injection)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Brown University | Conditions: Glioblastoma Multiforme, Glioblastoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-02-24